Investors in Guangzhou Kingmed Diagnostics Group (SHSE:603882) Have Unfortunately Lost 77% Over the Last Three Years
Investors in Guangzhou Kingmed Diagnostics Group (SHSE:603882) Have Unfortunately Lost 77% Over the Last Three Years
As every investor would know, not every swing hits the sweet spot. But really big losses can really drag down an overall portfolio. So spare a thought for the long term shareholders of Guangzhou Kingmed Diagnostics Group Co., Ltd. (SHSE:603882); the share price is down a whopping 78% in the last three years. That'd be enough to cause even the strongest minds some disquiet. The more recent news is of little comfort, with the share price down 54% in a year. Furthermore, it's down 19% in about a quarter. That's not much fun for holders. Of course, this share price action may well have been influenced by the 12% decline in the broader market, throughout the period.
每個投資者都知道,不是每一次動作都能擊中甜點。但是巨大的虧損會嚴重拖累整個投資組合。因此,請爲金域醫學股份有限公司的長期股東着想(SHSE:603882);股價在過去的三年中慘跌78%。即使是最強大的頭腦也會感到不安。最近的消息也沒有太多安慰,股價在一年內下跌了54%。此外,大約一個季度下跌了19%。這對持有者來說並不好玩。當然,在這段時間內,股價的走勢可能受到了市場整體下跌12%的影響。
Since shareholders are down over the longer term, lets look at the underlying fundamentals over the that time and see if they've been consistent with returns.
由於股東們長期以來都虧損了,因此讓我們回顧過去一段時間的基本面,看看是否一直與收益相一致。
In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.
禾倫·巴菲特在他的文章《格雷厄姆與多德維爾的超級投資者》中描述了股票價格並不總是合理地反映了一家企業的價值。考慮市場對一家公司的看法如何轉變的一種不完美但簡單的方法,是將每股收益(EPS)的變化與股價的動態進行比較。
Guangzhou Kingmed Diagnostics Group saw its EPS decline at a compound rate of 38% per year, over the last three years. The 40% average annual share price decline is remarkably close to the EPS decline. That suggests that the market sentiment around the company hasn't changed much over that time, despite the disappointment. It seems like the share price is reflecting the declining earnings per share.
金域醫學的每股收益以複合年均38%的速度下降,在過去的三年中。40%的年均股價下跌與每股收益下降非常接近。這表明市場對公司的情緒在這段時間內並沒有多大的變化,儘管令人失望。看起來股價反映了每股收益下降。
The image below shows how EPS has tracked over time (if you click on the image you can see greater detail).
下圖顯示了EPS隨時間的變化情況(如果您單擊該圖像,則可以查看更多詳細信息)。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240812/0-d2d0e6241b6da97fd4d930e8fa01eed3-0-14fe7f8675f18bd7467b47c204b183f7.png/big)
This free interactive report on Guangzhou Kingmed Diagnostics Group's earnings, revenue and cash flow is a great place to start, if you want to investigate the stock further.
如果您想進一步調查該股票,則廣州金域醫學集團的免費交互式報告涵蓋了其收益、營業收入和現金流等方面,是一個很好的起點。
A Different Perspective
不同的觀點
We regret to report that Guangzhou Kingmed Diagnostics Group shareholders are down 53% for the year (even including dividends). Unfortunately, that's worse than the broader market decline of 18%. However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 6% per year over five years. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Consider for instance, the ever-present spectre of investment risk. We've identified 3 warning signs with Guangzhou Kingmed Diagnostics Group , and understanding them should be part of your investment process.
我們很遺憾地報告說,廣州金域醫學集團的股東在今年下跌了53%(包括分紅在內)。不幸的是,這比整個市場下跌18%還要糟糕。然而,它可能僅僅是因爲股價受到了整個市場的擔憂影響。如果有好的機會的話,認真研究基本面可能是值得的。遺憾的是,去年的表現結束了一段糟糕的運營,股東面臨着每年6%的總虧損。總的來說,長期股價疲軟可能是一個不好的跡象,儘管背道而馳的投資者可能希望研究股票,以期翻轉局面。雖然考慮市場條件可能對股價產生不同的影響很值得,但其他因素更爲重要。例如,始終存在的投資風險。我們已經確定了3個警告信號與金域醫學有關,並且了解它們應該成爲您的投資過程的一部分。
But note: Guangzhou Kingmed Diagnostics Group may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).
但請注意:金域醫學可能不是最好的股票買入選擇。因此,請查看此免費的利潤增長過去(以及進一步的增長預測)的有趣公司列表。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
請注意,本文引用的市場回報反映了目前在中國交易所上市的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。